Assignee
EUCURE BEIJING BIOPHARMA CO LTD
CN·8 granted patents·9 pending applications·4 citations·filing 2020–2024
Top patents by PatentIndex Score
17 records- 0189US10934365B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Mar 2, 2021·2 cites·25 claims
- 0285US11142582B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Oct 12, 2021·1 cites·14 claims
- 0382US11034764B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Jun 15, 2021·1 cites·18 claims
- 0480US2025034271A1Anti-cd40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0580US2025034256A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0679US2024343806A1Anti-ctla4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0778US2024352141A1Anti-ox40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0877US2024092922A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 0972US12134653B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Nov 5, 2024·0 cites·16 claims
- 1070US2022251229A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 1169US11292849B2Anti-TNFRSF9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Apr 5, 2022·0 cites·33 claims
- 1267US12054547B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Aug 6, 2024·0 cites·18 claims
- 1367US11999790B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Jun 4, 2024·0 cites·17 claims
- 1467US2021403570A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 1565US11155625B2Anti-PD-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Oct 26, 2021·0 cites·43 claims
- 1657US2023220082A1Anti-pd-1/cd40 bispecific antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1751US2022073621A1Anti-pd-l1 antibody and use thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EUCURE BEIJING BIOPHARMA CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →